Gilead Sciences, Inc.’s oncology business made its biggest contribution yet to the company’s sales as revenue from the COVID-19 drug Veklury (remdesivir) fell in the second quarter, while sales of the company’s HIV drugs continued to see a return to growth.
The drug maker reported its second quarter sales and earnings on 2 August, with total revenues of $6.3bn representing a...








